Create account

Coverage dated March 31, 2026 to April 1, 2026

FDA approves Foundayo, Eli Lilly's new GLP-1 obesity pill

Headline from FOX 5 DC, from the development of Apr 1, 2026

Newest development Apr 2, 2026 · 2 reportsFDA approves new daily GLP-1 pill — what to know, including how they compare to Wegovy tablets

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold as Foundayo.

FOX 5 DC's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Developments in this update

2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.

  1. Names this update

    FDA approves Foundayo, Eli Lilly's new GLP-1 obesity pill

    Headline from FOX 5 DC ·

  2. Newest

    FDA approves new daily GLP-1 pill — what to know, including how they compare to Wegovy tablets

    Headline from New York Post ·

Read the reports

Reports & sources

23 articles, oldest first.

  1. FOX 5 DC

    FDA approves Foundayo, Eli Lilly's new GLP-1 obesity pill (opens FOX 5 DC)

    Published

    FOX 5 DC's feed description

    The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold as Foundayo.

  2. MyNorthwest

    FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity (opens MyNorthwest)

    Published

    MyNorthwest's feed description

    Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.

  3. NBC News

    FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly (opens NBC News)

    Published

    NBC News's feed description

    A new daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the FDA approval of Novo Nordisk’s Wegovy pill.

  4. Newsweek

    FDA approves Eli Lilly weight-loss pill Foundayo: what to know (opens Newsweek)

    Published

    Newsweek's feed description

    FDA approves Eli Lilly’s daily weight‑loss pill Foundayo, a fast‑tracked GLP‑1 drug offering a new oral option for obesity treatment.

  5. CNN

    Another GLP-1 weight loss pill gets FDA approval, and it has fewer restrictions on how it’s used (opens CNN)

    Published

    CNN's feed description

    The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies.

  6. The Guardian

    US approves new oral weight-loss pill developed by Eli Lilly (opens The Guardian)

    Published

    The Guardian's feed description

    Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

  7. Honolulu Star-Advertiser

    Lilly weight-loss pill wins FDA approval, market battle heats up | Honolulu Star-Advertiser (opens Honolulu Star-Advertiser)

    Published

    Honolulu Star-Advertiser's feed description

    The FDA today approved Eli Lilly’s weight-loss pill, setting up the next battle with Novo Nordisk for the millions of Americans seeking highly effective GLP-1 medicines.

  8. Forbes

    FDA Approves Eli Lilly’s Weight Loss Pill Foundayo—Fewer Food And Drink Restrictions (opens Forbes)

    Published

    Forbes's feed description

    Lilly says Foundayo was approved to treat obesity and can lead to long-term weight loss, alongside diet and exercise.

  9. New York Post

    FDA approves new daily GLP-1 pill — what to know, including how they compare to Wegovy tablets (opens New York Post)

    Published

    New York Post's feed description

    The new Foundayo pill, also known as orforglipron, offers a more convenient way to receive life-changing obesity medication.

  10. Fox News

    New weight-loss pill hits the market, promising 'greater flexibility' (opens Fox News)

    Published

    Fox News's feed description

    Foundayo (orforglipron), a new once-daily oral GLP-1 pill developed by Eli Lilly, has received FDA approval for weight loss in adults with obesity or overweight.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

FDA approves Foundayo, Eli Lilly's new GLP-1 obesity pill | Since Then